CA3060336A1 - Coversin variants lacking c5 binding - Google Patents
Coversin variants lacking c5 binding Download PDFInfo
- Publication number
- CA3060336A1 CA3060336A1 CA3060336A CA3060336A CA3060336A1 CA 3060336 A1 CA3060336 A1 CA 3060336A1 CA 3060336 A CA3060336 A CA 3060336A CA 3060336 A CA3060336 A CA 3060336A CA 3060336 A1 CA3060336 A1 CA 3060336A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- replaced
- modified coversin
- fragment
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706406.4 | 2017-04-21 | ||
| PCT/EP2018/060240 WO2018193121A1 (en) | 2017-04-21 | 2018-04-20 | Coversin variants lacking c5 binding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3060336A1 true CA3060336A1 (en) | 2018-10-25 |
Family
ID=58795719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3060336A Pending CA3060336A1 (en) | 2017-04-21 | 2018-04-20 | Coversin variants lacking c5 binding |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11214602B2 (enExample) |
| EP (1) | EP3612207B1 (enExample) |
| JP (1) | JP7183180B2 (enExample) |
| KR (1) | KR102630702B1 (enExample) |
| CN (1) | CN110799207B (enExample) |
| AU (1) | AU2018253961B2 (enExample) |
| CA (1) | CA3060336A1 (enExample) |
| ES (1) | ES2980279T3 (enExample) |
| GB (1) | GB201706406D0 (enExample) |
| IL (1) | IL269856B2 (enExample) |
| PL (1) | PL3612207T3 (enExample) |
| WO (1) | WO2018193121A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831617A (zh) * | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2023503776A (ja) | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030077709A1 (en) * | 2000-03-21 | 2003-04-24 | Masazumi Kamohara | Novel leukotriene B4 receptor |
| CA2481231A1 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
| US7884188B2 (en) | 2003-06-02 | 2011-02-08 | Varleigh Immuno Pharmaceuticals (Vip) Ltd | Complement inhibitors |
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2008113834A2 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| GB201410031D0 (en) | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| WO2016198133A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
-
2017
- 2017-04-21 GB GBGB1706406.4A patent/GB201706406D0/en not_active Ceased
-
2018
- 2018-04-20 PL PL18719169.7T patent/PL3612207T3/pl unknown
- 2018-04-20 JP JP2019556928A patent/JP7183180B2/ja active Active
- 2018-04-20 CA CA3060336A patent/CA3060336A1/en active Pending
- 2018-04-20 EP EP18719169.7A patent/EP3612207B1/en active Active
- 2018-04-20 CN CN201880040770.5A patent/CN110799207B/zh active Active
- 2018-04-20 AU AU2018253961A patent/AU2018253961B2/en active Active
- 2018-04-20 KR KR1020197031710A patent/KR102630702B1/ko active Active
- 2018-04-20 WO PCT/EP2018/060240 patent/WO2018193121A1/en not_active Ceased
- 2018-04-20 US US16/603,357 patent/US11214602B2/en active Active
- 2018-04-20 IL IL269856A patent/IL269856B2/en unknown
- 2018-04-20 ES ES18719169T patent/ES2980279T3/es active Active
-
2021
- 2021-11-18 US US17/529,534 patent/US20230002456A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL269856B2 (en) | 2024-09-01 |
| CN110799207A (zh) | 2020-02-14 |
| EP3612207C0 (en) | 2024-04-10 |
| PL3612207T3 (pl) | 2024-09-23 |
| GB201706406D0 (en) | 2017-06-07 |
| US11214602B2 (en) | 2022-01-04 |
| EP3612207B1 (en) | 2024-04-10 |
| EP3612207A1 (en) | 2020-02-26 |
| WO2018193121A1 (en) | 2018-10-25 |
| CN110799207B (zh) | 2024-05-03 |
| IL269856A (en) | 2019-11-28 |
| AU2018253961A1 (en) | 2019-10-31 |
| IL269856B1 (en) | 2024-05-01 |
| US20230002456A1 (en) | 2023-01-05 |
| JP2020517260A (ja) | 2020-06-18 |
| KR20190141163A (ko) | 2019-12-23 |
| US20200385434A1 (en) | 2020-12-10 |
| ES2980279T3 (es) | 2024-09-30 |
| JP7183180B2 (ja) | 2022-12-05 |
| KR102630702B1 (ko) | 2024-01-29 |
| AU2018253961B2 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018253961B2 (en) | Coversin variants lacking C5 binding | |
| EP3047024B1 (en) | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders | |
| AU2009211257A1 (en) | Treatment of diseases and conditions mediated by eicosanoids | |
| KR20140054009A (ko) | 릴랙신 융합 폴리펩타이드 및 그의 용도 | |
| KR20120036947A (ko) | 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법 | |
| KR20140129163A (ko) | 인간 보체 c5에 결합하는 폴리펩티드 | |
| CN110896606B (zh) | 用于治疗自身免疫性水疱病的coversin | |
| DK2393831T3 (en) | MODIFIED OMCI AS COMPLEMENT INHIBITOR | |
| FR2972006A1 (fr) | Nouveaux fragments d'il-33 superactifs et leurs utilisations | |
| KR101810551B1 (ko) | B세포 활성인자길항제 및 그의 제조방법과 용도 | |
| KR20220137876A (ko) | 조직 재생의 촉진에 유용한 hmgb1과 관련된 폴리펩티드, 이를 포함하는 조성물, 및 이들의 용도 | |
| EP3419994B1 (en) | Peptide inhibitors of calcium channels | |
| WO2013156771A1 (en) | Anti-atherogenic peptides | |
| CN102028935A (zh) | 败血症以及败血症休克的预测、预防和治疗方法及试剂盒 | |
| JP5312025B2 (ja) | Ｉｌ−３２モジュレーター | |
| CN100480264C (zh) | 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列 | |
| CN111440227B (zh) | 一种抑制肿瘤转移及骨肿瘤的多肽及其应用 | |
| WO2025172720A1 (en) | Fragment of complement factor h related protein 5 which restores complement regulation | |
| CN103059110A (zh) | 白念珠菌细胞凋亡促进因子基因及其用途 | |
| CN1343688A (zh) | 人nip2相关蛋白和编码序列及其用途 | |
| JP2002517220A (ja) | ヒト腎臓特異的遺伝子ｋｋ８６ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230419 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |